These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33737341)

  • 1. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
    Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.
    Sluijter BJ; van den Hout MF; Koster BD; van Leeuwen PA; Schneiders FL; van de Ven R; Molenkamp BG; Vosslamber S; Verweij CL; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Res; 2015 May; 3(5):495-505. PubMed ID: 25633713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
    Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
    Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8
    Rotman J; Heeren AM; Gassama AA; Lougheed SM; Pocorni N; Stam AGM; Bleeker MCG; Zijlmans HJMAA; Mom CH; Kenter GG; Jordanova ES; de Gruijl TD
    Clin Cancer Res; 2020 Jul; 26(14):3791-3802. PubMed ID: 32220890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation.
    van de Ven R; van den Hout MF; Lindenberg JJ; Sluijter BJ; van Leeuwen PA; Lougheed SM; Meijer S; van den Tol MP; Scheper RJ; de Gruijl TD
    Blood; 2011 Sep; 118(9):2502-10. PubMed ID: 21750314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
    Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
    van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
    Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The In Vitro Differentiation of Human CD141+CLEC9A+ Dendritic Cells from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells.
    Swartz AM; Nair SK
    Curr Protoc; 2022 Apr; 2(4):e410. PubMed ID: 35435334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Koster BD; van den Hout MFCM; Sluijter BJR; Molenkamp BG; Vuylsteke RJCLM; Baars A; van Leeuwen PAM; Scheper RJ; Petrousjka van den Tol M; van den Eertwegh AJM; de Gruijl TD
    Clin Cancer Res; 2017 Oct; 23(19):5679-5686. PubMed ID: 28972083
    [No Abstract]   [Full Text] [Related]  

  • 17. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BDCA3(+)CLEC9A(+) human dendritic cell function and development.
    van der Aa E; van Montfoort N; Woltman AM
    Semin Cell Dev Biol; 2015 May; 41():39-48. PubMed ID: 24910448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
    Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
    Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
    Di Gennaro P; Gerlini G; Caporale R; Sestini S; Brandani P; Urso C; Pimpinelli N; Borgognoni L
    Cancer Lett; 2018 Mar; 417():124-130. PubMed ID: 29306022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.